Trending

#OGEN

Latest posts tagged with #OGEN on Bluesky

Latest Top
Trending

Posts tagged #OGEN

Preview
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION Oragenics (NYSE American: OGEN) completed the first site initiation visit for its Phase IIa trial of ONP-002 in Australia on March 12, 2026.First SIV finished at one of three planned Australian sites; two remaining sites are completing Research Governance Office reviews after Human Research Ethics Committee approval. The randomized, placebo-controlled trial targets 40 patients, dosing within 12 hours of concussion onset, with primary endpoints around safety, neurocognitive assessments, and tolerability.

#OGEN ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

www.stocktitan.net/news/OGEN/oragenics-init...

0 0 0 0

Zij zien hoe #Iraanse #islamisten niet alleen #Joden, #Koerden, #christenen en andere #minderheden #vermoorden, maar vooral ook #moslims,

en ze begrijpen niet dat zoveel #westerlingen de #ogen #hiervoor #sluiten":

0 0 0 0
Preview
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION Oragenics (NYSE American: OGEN) is exploring acquisition of CNS assets focused on brain health and brain recovery to complement its intranasal delivery platform and lead candidate ONP-002.ONP-002 Phase IIa is in active site initiation in Australia; Phase 1 showed safety in 40 patients with zero serious adverse events. No definitive acquisition agreements have been reached; any material transaction will be disclosed as required.

#OGEN ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

www.stocktitan.net/news/OGEN/oragenics-expl...

0 0 0 0
Preview
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia Oragenics (NYSE: OGEN) received final Human Research Ethics Committee (HREC) approval in Australia to begin a randomized, placebo-controlled Phase IIa trial of ONP-002 for concussion/mild traumatic brain injury. The trial will enroll 40 patients across three Australian sites, with first dosing expected before the end of March 2026 and a data readout projected before year-end 2026. Patients will receive first dosing within 12 hours of injury and up to 30 days of treatment; the company cites a Phase 1 safety profile with zero serious adverse events. Trial management is expected to be handled by Southern Star Research.

#OGEN Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

www.stocktitan.net/news/OGEN/oragenics-rece...

0 0 0 0
Post image

Itsy Bitsy Anansie - 24 feb 2026

2 #meisjes wilen dit #plaatje op het #krijtbord. Mmmm... Ik zeg dat ik de #spin thuis op de #muur ga #tekenen. Ze kijken me met #grote #ogen aan. Ik #hoop (niet) dat ik ze op #ideeën heb gebracht 🤭 #handlettering #theoffice // #fotodagboek #photodiary #since2009

0 0 0 0

Het begint erop te lijken dat de opdrachtgevers & onderzoekers denken dat Nederlandse burger gek is.
Conclusies staan #haaks op wat veel mensen met #eigen #ogen #dagelijks aanschouwen.
Er komen moskeeën & islamitische scholen bij, statushouders krijgen voorrang op krappe markt sociale #huurwoningen.

0 0 0 1

Mmm... met 12 prisma's in de nieuwe brillenglazen kan de bestelling niet op normale manier. Dus ik word opnieuw uitgenodigd voor het inmeten van het montuur. Wel alles al uitgezocht. Ik verheug me wel op beter zicht. Klachten zii verder toe te schrijven aan de leeftijd☺️
#optometrist
#ogen
#bijziend

0 0 0 0

Stop die bom onder het #Vuurwerkverbod!

Het is genoeg geweest.
#vuurwerkbom

#geleidehond
#vogelbescherming

#ogen open!

1 0 0 0

Zijn er tegenwoordig veel meer oogklachten dan vroeger, door hoeveel er naar schermen wordt gekeken van computers en smartphones en al.

En wanneer gaan onze ogen evolueren.

#Ogen #Onderzoek

1 0 0 0

Wat veroorzaakt er geel oogwit.

#Onderzoek #Medisch #GeelOogwit #Ogen

1 0 0 0
Post image Post image Post image

Bij de ogen van Vogel Rok lijkt de zwarte laag aan de binnenkant los te raken. Op eerdere foto's (2 en 3) zag ik dat in de ogen niet zitten.

#Efteling #VogelRok #Ogen

6 0 1 0
Original post on mastodon.social

De gemiddelde (!) leeftijd voor amputaties door illegaal vuurwerk is gezakt naar 13 jaar. Dat zegt veel over degenen die dit illegale vuurwerk kopen of in handen geven van jongeren. Want het is niet zo dat de risico’s hiervan niet algemeen bekend zijn.
#IllegaalVuurwerk
#Amputaties
#Oren
#Ogen […]

0 1 1 0

Idee:
Foto maken van het oog en kijken of het oogwit wel wit is met kleurcode bekijken, in een foto bewerkingsprogramma.
Witte muur wit op de foto, dan hoort het oogwit ook wit te zijn.

#Ogen #Medisch

0 0 0 0

Idee.
Kijken of het oogwit wel wit is met wit textiel.
Wit textiel vlakbij het oog houden om te kijken of het oogwit wel wit is. Vergelijken.
-Het oog niet raken met het textiel

Natuurlijk licht heel belangrijk, geel achtig lamp licht kan wit wat geel doen lijken.

#Ogen #Medisch #Idee

0 0 0 0
Preview
Oragenics Q3 2025 Shareholder Update Oragenics (NYSE American: OGEN) reported Q3 2025 operational, strategic, and financial milestones as it prepares for Phase IIa clinical work in Australia with anticipated initiation in Q4 2025–Q1 2026. Key achievements include regaining NYSE American compliance on Oct 20, 2025, completing a $16.5M gross capital raise (net proceeds ~$15.2M), eliminating a $3M note payable, securing HREC approval earlier in 2025 with amendments under review, appointing Southern Star Research as CRO, and contracting Sterling Pharma Solutions for cGMP manufacturing. The company also announced a strategic AI collaboration with Receptor.AI to accelerate its molecule pipeline beyond ONP-002 and reported year-to-date R&D expense reduction of 30%.

#OGEN Oragenics Q3 2025 Shareholder Update

www.stocktitan.net/news/OGEN/oragenics-q3-2...

0 0 0 0
Preview
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency Oragenics (NYSE American: OGEN) regained full NYSE American compliance effective October 20, 2025 after restoring stockholders' equity above the required $6 million threshold.The company closed a $16.5 million public offering of Series H convertible preferred stock on July 2, 2025, which restored equity and provides runway to advance lead candidate ONP-002 through Phase IIa in Australia and to prepare for potential U.S. Phase IIb trials.

#OGEN Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

www.stocktitan.net/news/OGEN/oragenics-rega...

0 0 0 0

Altijd dwars in het pad. En die gevangen mensen zijn toch veel te groot. #ogen #maag 🤦🏼

1 0 1 0
Preview
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development Oragenics (NASDAQ: OGEN) announced a strategic collaboration with Receptor.AI to apply AI-driven receptor profiling to Oragenics' molecules acquired in 2023, aiming to accelerate preclinical candidate identification for neurological and psychiatric indications. The work intends to guide laboratory validation and prioritize targets across Alzheimer’s, Parkinson’s, PTSD, opioid addiction, and anxiety. Oragenics remains focused on advancing its lead candidate, ONP-002, with a Phase IIa concussion trial initiation expected in Q4 2025. The company frames the partnership as a step from a single-asset model toward a diversified intranasal neurology platform while emphasizing capital-efficient discovery.

#OGEN Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

www.stocktitan.net/news/OGEN/oragenics-anno...

0 0 0 0

Onderzoek: kan laser microfoon schadelijk zijn voor de ogen

#Onderzoek #LaserMicrofoon #Microfoon #Afluisteren #Ogen #Schadelijk

1 0 0 0

Briljante foto. #ogen

0 0 0 0
Post image

Drew this on wplace! (Inspired by @axlewaterphenix3.bsky.social's art of me)
#art #wplace #protogen #furry #furryart #pixel #pixelart #proot #proto #prot #pootog #pro #potog #pogen #pototogrotogen #progototgen #pot #prot #ogen #negotorp #pr #oto #gen #proataugeen #prot #proootooogeeen #rpotogen #prt

19 1 1 0
Preview
Oragenics Q2 2025 Shareholder Update Oragenics (NYSE American: OGEN) provided a Q2 2025 shareholder update highlighting progress in developing ONP-002, its lead candidate for concussion treatment. The company secured a $16.5 million capital raise through Series H Convertible Preferred Stock and Warrants, with net proceeds of $15.2 million.Key operational achievements include HREC approval in Australia, appointment of Southern Star Research as CRO, and a cGMP manufacturing agreement with Sterling Pharma Solutions. The company demonstrated financial discipline with a 50% reduction in R&D expenses and 8% decrease in administrative costs.Oragenics plans to initiate Phase IIa trials in Q3 2025, followed by IND submission to FDA for Phase IIb trials in Q3-Q4 2025. The company targets the $8.9 billion global concussion market by 2027, aiming to become the first FDA-approved pharmacological treatment for concussion.

#OGEN Oragenics Q2 2025 Shareholder Update

www.stocktitan.net/news/OGEN/oragenics-q2-2...

0 0 0 0
Preview
Revolutionary Intranasal Concussion Drug Enters Phase 2 Trial: Oragenics Partners with Leading CRO Oragenics selects Southern Star Research to conduct Phase 2a trial of ONP-002, its innovative intranasal concussion treatment. See trial timeline details.

#OGEN Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

www.stocktitan.net/news/OGEN/oragenics-sele...

0 0 0 0
Preview
Breakthrough Concussion Drug Enters US Production as Oragenics Prepares for Critical Phase 2 Trial First-of-its-kind concussion treatment ONP-002 begins US production for upcoming Phase IIb trials. Sterling Pharma partnership accelerates development timeline. Learn more.

#OGEN Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

www.stocktitan.net/news/OGEN/oragenics-inc-...

0 0 0 0
Preview
Oragenics Secures $16.5M Funding, Eyes Additional $16.5M for Breakthrough Brain Injury Drug Development New funding accelerates ONP-002 intranasal drug development for concussion treatment. See how $33M potential total raise could transform brain injury care. Get details.

#OGEN Oragenics Completes Approximately $16.5 Million Offering

www.stocktitan.net/news/OGEN/oragenics-comp...

0 0 0 0

BREAKING NEWS: ( NYSE: #OGEN ) PRISM Mid-Day Movers: Medicare Milestone and Energy Innovation Drive Index Gains

0 0 0 0

Breaking News: ( NYSE: #OGEN ) BioMedNewsBreaks - Oragenics Inc. (NYSE American: OGEN) Announces $20 Million Preferred Stock and Warrant Offering

0 0 0 0
Video

Top 6 Momentum Stocks Under $10 July 01, 2025 - 2 stocks surged to close over 100% - $OGEN $1.55 (112%), $WOLF $0.79 (108%), $ARBK $0.37 (89%), $MBIO $2.05 (85%), $VERO $2.62 (53%), $CURR $1.05 (34%) #OGEN #financialfreedom #pennystocks #swingtrading

0 0 0 0
Preview
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June - Aeva Technologies (NASDAQ:AEVA), ATAI Life Sciences (NASDAQ:ATAI)

Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June read more

#AEVA #ATAI #CLRO #Earnings #Equities #Mid #Day #Market #Update #News #OGEN

Origin | Interest | Match

0 0 0 0
Preview
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants Oragenics (NYSE American: OGEN), a company developing intranasal pharmaceuticals for neurological disorders, has announced the pricing of a public offering of up to 800,000 shares of Series H Convertible Preferred Stock and Warrants. The combined offering price is set at $25.00 per unit, with the potential to raise up to $20 million in gross proceeds.The Preferred Stock is convertible into common stock at $2.50 per share, and the Warrants allow purchase of additional Preferred Stock at $25.00 per share. The offering is expected to close around July 2, 2025. Dawson James Securities is serving as the sole placement agent.The company plans to use the proceeds to fund its ONP-2 concussion clinical trials, related R&D activities, repay a $3 million bridge note, and for working capital and general corporate purposes.

#OGEN Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

www.stocktitan.net/news/OGEN/oragenics-inc-...

0 0 0 0